The White House did not directly deny speculation that Eli Lilly's experimental obesity drug retatrutide recipient could be President Donald Trump, fueling public curiosity.

Overview of Compassionate Use Program A 79-year-old individual has been granted rare early access to Eli Lilly's experimental obesity treatment, retatrutide, through the FDA's compassionate use initiative.

In 1970, about 1 in 20 children were affected by obesity; today, it's 1 in 5. Dr. Jonathan LaPook looks at programs aimed at helping kids (and their families) get healthy the old-fashioned way, by eating right and exercising.

Everyone is still arguing about Novo Nordisk (NYSE:NVO | NVO Price Prediction), the Danish obesity juggernaut whose GLP-1 franchise turned Wegovy and Ozempic into household names and dragged the entire pharma sector into a multi-year hype cycle.

A new 'living guideline' from the American College of Physicians (ACP) recommends semaglutide (Wegovy) and tirzepatide (Zepbound) as first-line medications for adults with obesity.

The obesity treatment landscape is changing fast, with GLP-1 drugs opening the door to more effective care than ever before. Experts now envision a future where medications, minimally invasive procedures,